Two ex vivo modelswere used from AML patients and healthy donors: CD34+ liquid HSC (hematopoieticstem cell) culture as a short-term model and CFU-E (colony-formingunit–erythroid) as a midterm model. Here, CD34 is linked to acute myeloid leukemia.